Beam Therapeutics reported a net loss of $112.7 million for the third quarter of 2025, or $1.10 per share, and revenue of $9.7 million, both figures below analyst expectations.
The quarter’s loss widened from the $96.7 million net loss ($1.17 per share) reported for Q3 2024, while revenue fell from $14.27 million to $9.7 million. In Q2 2025 the company posted a $102.3 million loss ($1.00 per share) on $8.47 million in revenue. Research and development expenses rose to $109.8 million from $94.3 million year‑over‑year, reflecting continued investment in clinical programs.
Beam’s cash, cash‑equivalent, and marketable‑security balance stood at $1.1 billion, a reserve that management expects will fund operations through 2028.
Clinical progress included ongoing enrollment and dosing in the BEAM‑302 Phase 1/2 trial for alpha‑1 antitrypsin deficiency, the initiation of dosing for the ESCAPE anti‑CD117 antibody in a healthy‑volunteer study, and the planned presentation of BEACON Phase 1/2 BEAM‑101 data for sickle cell disease at the American Society of Hematology meeting in December 2025.
Management highlighted continued investment in its base‑editing platform and the company’s focus on advancing its gene‑editing pipeline.
No forward guidance was issued in the release.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.